Move Over Mounjaro. Eli Lilly Has Another Blockbuster Opportunity in the Making, and No One Is Talking About It.
Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...
Jim Cramer on Eli Lilly and Company (LLY)’s Q4 2024 Performance: ‘Aren’t As Strong As Wall Street Was Hoping’
We recently compiled a list of the 9 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...
24/7 Wall St3d
This Best-of-Class Pharma Stock Could Soar 72% This Year According to Wall Street Insider
Eli Lilly (NYSE: LLY) doesn’t really need much of an introduction. It has become a household name due to its obesity and ...
Jim Cramer Says ‘Eli Lilly and Company (LLY)’s Drug Is Superior In Terms Of Weight Reduction At The Same Dose’
We recently compiled a list of the Jim Cramer Recently Discussed These 17 Stocks And Chinese Hackers. In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands ...
Relay Therapeutics Inc (RLAY): AI-Driven Cancer Treatments Backed by Barclays’ $17 Price Target
Relay Therapeutics Inc. (NASDAQ:RLAY) is a leading clinical-stage precision medicines firm focused on cancer treatments. The ...
5 Best Recommended Stocks to Buy
Truist Securities, TD Cowen, Citigroup Inc. ( C) and Canaccord Genuity all also rate BSX "buy," while JPMorgan Chase & Co. ( ...
Eli Lilly stock dips on Novo Nordisk's rival drug data
Novo Nordisk's phase 1b/2a clinical trial results revealed that their investigational drug, amycretin, led to an average ...
Eli Lilly: Market Overreacted
Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.